PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines

BACKGROUND: The US Food and Drug Administration (FDA) has approved several immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in other clinical studies. These inhibitors significantly increase response rates and result in the treatment of patients with advanced ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Safi, Mohammed, Ahmed, Hyat, Al-Azab, Mahmoud, Xia, Yun-long, Shan, Xiu, Al-radhi, Mohammed, Al-danakh, Abdullah, Shopit, Abdullah, Liu, Jiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020146/
https://www.ncbi.nlm.nih.gov/pubmed/33842004
http://dx.doi.org/10.1016/j.jare.2020.09.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020146/
https://www.ncbi.nlm.nih.gov/pubmed/33842004
http://dx.doi.org/10.1016/j.jare.2020.09.006

Ejemplares similares